A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis-The Rise of IGF-BP2 and GDF-15.

Joseph Kletzer, Stefan Hecht (First author), Susanne Ramsauer, Bernhard Scharinger (Co-author), Reinhard Kaufmann (Co-author), Jürgen Kammler, Jörg Kellermair, Kaveh Akbari, Hermann Blessberger, Clemens Steinwender, Klaus Hergan (Co-author), Uta Hoppe (Co-author), Michael Lichtenauer (Co-author), Elke Boxhammer* (Last author)

*Corresponding author for this work

Research output: Contribution to journalOriginal Article (Journal)peer-review

3 Citations (Web of Science)

Abstract

(1) Background: Currently, echocardiography is the primary non-invasive diagnostic method used to screen patients with severe aortic valve stenosis (AS) for pulmonary hypertension (PH) by estimating systolic pulmonary artery pressure (sPAP). Other radiological methods have been a focus of research in the past couple of years, as it was shown that by determining the pulmonary artery (PA) diameter, prognostic statements concerning overall mortality could be made in these patients. This study compared established and novel cardiovascular biomarkers with the PA/BSA value to detect PH in patients with severe AS. (2) Methods: The study cohort comprised 188 patients with severe AS undergoing transcatheter aortic valve replacement (TAVR), who were then divided into two groups based on PA/BSA values obtained through CT-angiography. The presence of PH was defined as a PA/BSA >= 16.6 mm/m(2) (n = 81), and absence as a PA/BSA < 16.6 mm/m(2) (n = 107). Blood samples were taken before TAVR to assess cardiovascular biomarkers used in this study, namely brain natriuretic peptide (BNP), cardiac troponin I (cTnI), high-sensitive troponin (hsTN), soluble suppression of tumorigenesis-2 (sST2), growth/differentiation factor 15 (GDF-15), heart-type fatty acid-binding protein (H-FABP), insulin-like growth factor binding protein 2 (IGF-BP2), and soluble urokinase-type plasminogen activator receptor (suPAR). (3) Results: Patients with a PA/BSA >= 16.6 mm/m(2) showed significantly higher levels of BNP (p = <0.001), GDF-15 (p = 0.040), and H-FABP (p = 0.007). The other investigated cardiovascular biomarkers did not significantly differ between the two groups. To predict a PA/BSA >= 16.6 mm/m(2), cut-off values for the biomarkers were calculated. Here, GDF-15 (p = 0.029; cut-off 1172.0 pg/mL) and BNP (p < 0.001; cut-off 2194.0 pg/mL) showed significant results. Consequently, analyses of combined biomarkers were performed, which yielded IGF-BP2 + BNP (AUC = 0.721; 95%CI = 0.585-0.857; p = 0.004) as the best result of the two-way analyses and GDF-15 + IGF-BP2 + BNP (AUC = 0.727; 95%CI = 0.590-0.864; p = 0.004) as the best result of the three-way analyses. No significant difference regarding the 1-year survival between patients with PA/BSA < 16.6 mm/m(2) and patients with PA/BSA >= 16.6 mm/m(2) was found (log-rank test: p = 0.452). (4) Conclusions: Although PA/BSA aims to reduce the bias of the PA value caused by different body compositions and sizes, it is still a controversial parameter for diagnosing PH. Combining the parameter with different cardiovascular biomarkers did not lead to a significant increase in the diagnostic precision for detecting PH in patients with severe AS.
Original languageEnglish
Article number22
Number of pages20
JournalJOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 2023

Keywords

  • IMPLANTATION
  • REPLACEMENT
  • DYSFUNCTION
  • PRESSURE
  • IMPACT

Fingerprint

Dive into the research topics of 'A Story of PA/BSA and Biomarkers to Diagnose Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis-The Rise of IGF-BP2 and GDF-15.'. Together they form a unique fingerprint.

Cite this